解痉药使用对炎症性肠病腹痛及阿片类药物使用的影响:一项基于人群的研究
该研究基于TriNetX Diamond Network数据库纳入85,859例炎症性肠病(IBD)患者,其中5,661例使用解痉药。倾向性评分匹配后每组5,629例,使用解痉药者随访时腹痛和阿片类药物使用率更高(p<0.001),且皮质类固醇使用、门诊和急诊就诊及住院可能性更高,但IBD相关并发症、手术或死亡率无差异。
要点
- 使用解痉药的IBD患者随访时腹痛和阿片类药物使用率更高(p<0.001)
- 倾向性匹配后,使用解痉药者1个月时腹痛率更高,与基线腹痛无关
- 无阿片类药物使用史者使用解痉药后随访时阿片类药物使用率更高(1.1% vs. 0.2%;p<0.001)
核心结论
- IBD患者使用解痉药与腹痛和阿片类药物使用增加相关,在无阿片类药物使用史患者中阿片类药物使用增加。
- 使用解痉药与皮质类固醇使用、门诊和急诊就诊及住院可能性增加相关。
- IBD相关并发症、手术或死亡率无差异。
研究设计与样本
- 基于TriNetX Diamond Network医疗和索赔数据库的回顾性研究。
- 纳入85,859例IBD患者(中位年龄50岁;53.8%女性),其中5,661例使用解痉药。
- 按基线腹痛和阿片类药物使用分层,并进行倾向性匹配。
- 匹配后每组5,629例患者。
- 次要结局包括皮质类固醇使用、IBD相关并发症和手术、急诊就诊、住院和死亡率。
主要发现
- 随访时,使用解痉药者腹痛和阿片类药物使用率更高(p<0.001),无论基线腹痛或阿片类药物使用情况。
- 匹配后,使用解痉药者1个月时腹痛率更高,无论基线腹痛情况。
- 无阿片类药物使用史者使用解痉药后随访时阿片类药物使用率更高(1.1% vs. 0.2%;p<0.001)。
- 使用解痉药者皮质类固醇使用、门诊就诊、急诊就诊和住院可能性更高。
- IBD相关并发症、手术或死亡率无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with inflammatory bowel disease (IBD) are often prescribed antispasmodics for chronic abdominal pain. Large-scale data regarding efficacy and impact on clinical outcomes are lacking. AIM: To examine the association between antispasmodic use and outcomes of abdominal pain and opioid use before and after propensity matching key demographic and clinical characteristics. METHODS: We used TriNetX Diamond Network, a medical and claims database. Patients were stratified by baseline abdominal pain and opioid use. Secondary outcomes were corticosteroid use, IBD-related complications and surgeries, emergency room (ER) visits, hospitalisation and mortality. RESULTS: We included 85,859 patients (median age 50; 53.8% female) with IBD; 5661 used antispasmodics. On follow-up, those with antispasmodic use had higher rates of abdominal pain and opioid use (p < 0.001) regardless of baseline abdominal pain or opioid use. After matching, 5629 patients remained per group. Patients who used antispasmodics had higher rates of abdominal pain at 1 month, regardless of baseline abdominal pain. Opioid-naïve patients who used antispasmodics had higher rates of opioid use at follow-up (1.1% vs. 0.2%; p < 0.001). The likelihood of corticosteroid use, clinic visits, ER visits and hospitalisation were higher in those with antispasmodic use. No differences in IBD-related complications, surgery or mortality were observed. CONCLUSIONS: Antispasmodic use in patients with IBD was associated with increased abdominal pain and opioid use in opioid-naïve patients. Antispasmodic use was associated with increased likelihood of corticosteroid use, clinic and ER visits and hospitalisation.
引用
- Khunsriraksakul C, Ziegler O, Liu D, et al. The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population-Based Study. Aliment Pharmacol Ther. 2025. PMID: 40211901. doi:10.1111/apt.70147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。